雙調蛋白(AREG)單克隆抗體
Monoclonal Antibody to Amphiregulin (AREG)
AR; CRDGF; SDGF; Colorectum Cell-Derived Growth Factor; Schwannoma-Derived Growth Factor
- 編號MAA006Hu23
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)A7
- Ig亞型 IgG2b Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標記物無標記物
- 免疫原 RPA006Hu01-雙調蛋白(AREG)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 558 ¥ 1302 ¥ 1860 ¥ 4650 ¥ 18600
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Human Prostate cancer Tissue; Primary Ab: 20μg/ml Mouse Anti-Human AREG Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
DAB staining on IHC-P;
Sample: Human Pancreatic cancer Tissue;
Primary Ab: 20μg/ml Mouse Anti-Human AREG Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
DAB staining on IHC-P;
Sample: Human Breast cancer Tissue;
Primary Ab: 20μg/ml Mouse Anti-Human AREG Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
DAB staining on IHC-P;
Sample: Human Colorectal cancer Tissue;
Primary Ab: 20μg/ml Mouse Anti-Human AREG Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
DAB staining on IHC-P;
Sample: Human Liver cancer Tissue;
Primary Ab: 20μg/ml Mouse Anti-Human AREG Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
AF488 staining on IF;
Sample: Hela cell
Primary Ab: 30μg/ml Mouse Anti-Human AREG Antibody
Second Ab: 2μg/ml AF488-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu11)
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對AREG的小鼠單克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別AREG。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質期內，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| APA006Hu01 | 雙調蛋白(AREG)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA006Hu01 | 雙調蛋白(AREG)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA006Hu01 | 雙調蛋白(AREG)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA006Hu23 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA006Hu25 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA006Hu22 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC |
| MAA006Hu24 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC; ICC/IF |
| MAA006Hu26 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC |
| MAA006Hu21 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA006Hu27 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA006Hu29 | 雙調蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
| LAA006Hu76 | 雙調蛋白(AREG)單克隆抗體(生物素標記) | WB; IHC; ICC. |
| SEA006Hu | 雙調蛋白(AREG)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA006Hu | 雙調蛋白(AREG)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA006Hu | 雙調蛋白(AREG)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| PSA006Hu01 | 雙調蛋白(AREG)抗體對 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| KSA006Hu01 | 雙調蛋白(AREG)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Onkologie | Amphiregulin and Epiregulin Expression in Colorectal Carcinoma and the Correlation with Clinicopathological Characteristics [Karger: 315380] |
| Br J Cancer. | Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. [Pubmed:24800946] |
| Cancer Sci | Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer [PubMed: 25707609] |
| J Cancer Res Clin Oncol | Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer [PubMed: 26195282] |
| Oncotarget.? | Serum?level?of?hepatocyte?growth?factor?is a?novel?marker?of?predicting?theoutcome?and?resistance?to the?treatment?with?trastuzumab?in HER2-positive patients with metastatic gastric cancer [Pubmed:26716644] |
| Acta?Pharmacologica Sinica | Anti-asthmatic activity of alkaloid compounds from Pericarpium Citri Reticulatae (Citrus reticulata 'Chachi') [Pubmed: 19363516] |
| International Journal of Biological Sciences | CD9 regulates keratinocyte migration by negatively modulating the sheddase activity of ADAM17 [] |
| Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
| JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | Polarization of ADAM17‐driven EGFR signalling in electric field‐guided collective migration of epidermal sheets [Pubmed: 33164313] |
留言咨詢
